Short answer
Corvus Pharmaceuticals, Inc. (CRVS) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$14M
- −190.1% YoY
- EPS (diluted)
- −$0.15
- −15.4% YoY
Source: XBRL data from the Corvus Pharmaceuticals, Inc. (CRVS) Q1 2026 10-Q on SEC EDGAR. USD.
Corvus Pharmaceuticals, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly added or changed risk factors identified; filing presents principal risks carried forward from the 10-K
- Liquidity risk: $236.7 million in cash, equivalents, and marketable securities expected to fund operations into Q2 2028
- Financial performance risk: $13.7 million net loss for Q1 2026 versus $15.2 million net income in Q1 2025
- Regulatory risk: EU Clinical Trials Regulation fully governs all clinical trials following January 31, 2025 transition-period end
- Development risk: clinical-trial delays could increase costs and defer product revenue from soquelitinib, ciforadenant, and mupadolimab
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Corvus Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.